“Cutaneous Safety Profile of Nemolizumab in Moderate‑to‑Severe Atopic Dermatitis and Prurigo Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&2 and OLYMPIA 1&2) Nodularis: Pooled Analysis of Phase 3 Trials (ARCADIA 1&2 and OLYMPIA 1&2)”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s748, https://doi.org/10.25251/yghmqq47.